Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
RGS Protein Inhibitor
CCG 203769 is a selective inhibitor of the regulator of G protein signaling (RGS4), effectively disrupting the RGS4-Gαo protein-protein interaction with an IC50 of 17 nM. This compound is instrumental for research applications focused on G protein-coupled signaling pathways and the modulation of G protein activity. CCG 203769 may be utilized in studies exploring the role of RGS proteins in various physiological processes and disease states. -
RGS14 Inhibitor
Z55660043 is a selective inhibitor of Regulator of G protein Signaling-14 (RGS14) with an IC50 of 2.3 μM. This compound acts by non-covalently inhibiting the GTPase-accelerating protein (GAP) activity of RGS14, demonstrating a favorable safety profile without significant cytotoxic effects. Z55660043 is suitable for research focused on central nervous system and metabolic disorders, contributing to the understanding of RGS14's role in these biological processes. -
RGS4 Inhibitor
CCG-2046 is a selective inhibitor of the regulator of G-protein signaling 4 (RGS4), demonstrating an IC50 value of 4.3 μM for inhibiting the RGS4-Gαo interaction. This compound modulates G-protein signaling pathways, making it a valuable tool for studying their role in various physiological processes. CCG-2046 is suitable for research applications focused on neurobiology, cardiac function, and potential therapeutic interventions for related disorders. -
RGS Protein Inhibitor
CCG-4986 is a selective RGS protein inhibitor that covalently modifies the Cys-132 residue of RGS4, thereby inhibiting its activity. This compound is valuable for studying the implications of altered G protein-coupled receptor (GPCR) signaling in various pathological conditions, including Parkinson's disease and opioid addiction. CCG-4986 is a useful tool for researchers investigating the role of RGS proteins in cellular signaling pathways.

